Development and validation of a stability indicating UPLC-DAD method coupled with MS-TQD for ramipril and thymoquinone in bioactive SNEDDS with in silico toxicity analysis of ramipril degradation products Article Swipe
Ehab M. Elzayat
,
Abdelrahman Y. Sherif
,
Ahmad Abdul-Wahhab Shahba
,
Mohsin Kazi
,
Mohammed Alyahya
,
Hany W. Darwish
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1515/chem-2024-0070
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1515/chem-2024-0070
The identification of degradation products of therapeutic molecules in pharmaceutical formulations has gained significant attention due to their potential impact on patient safety. Ramipril (RP), an antihypertensive agent, was incorporated into a self-nanoemulsifying drug delivery system (SNEDDS), which greatly enhanced its bioavailability. However, none of the previous studies have investigated the toxicological effects of these degradation products that may form during storage. Moreover, a bioactive SNEDDS containing black cumin oil (BCO) and its bioactive ingredient, thymoquinone (TQ), was used to further enhance the therapeutic activity of RP. To assess the stability of the proposed formulation, a validated ultrahigh-performance liquid chromatography (UPLC) method was developed to simultaneously measure the concentrations of RP and TQ. The formulation was subjected to accelerated stress conditions to facilitate drug degradation. The resulting degradation products were analyzed using mass spectroscopy (MS) to determine their molecular mass, and their chemical structures were in silico predicted using Zeneth Nexus software, while their toxicity was assessed using in silico Derek Nexus software. RP and TQ, along with their degradation products, were separated using an HSS T3 column at a flow rate of 0.25 mL/min. The detection wavelengths for RP and TQ were 210 and 254 nm, respectively. The developed UPLC method exhibited acceptable linearity for both RP and TQ, with correlation coefficient ( r 2 ) values exceeding 0.9995 and 0.9998, respectively. The method provided accurate, precise, and high-resolution analysis of both drugs and their degradation products within a short run time of less than 3.2 min. The toxicity and mutagenicity of two alkaline degradation products of RP were predicted using in silico software Derek Nexus (version 6.3). Several toxicity endpoints, including chromosomal damage, skin sensitization, and hepatotoxicity, were predicted. Overall, the developed method can be used to evaluate the stability and integrity of RP and TQ during the development of the proposed antihypertensive formulation.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1515/chem-2024-0070
- https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdf
- OA Status
- gold
- Cited By
- 3
- References
- 46
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401243272
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401243272Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1515/chem-2024-0070Digital Object Identifier
- Title
-
Development and validation of a stability indicating UPLC-DAD method coupled with MS-TQD for ramipril and thymoquinone in bioactive SNEDDS with in silico toxicity analysis of ramipril degradation productsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-01-01Full publication date if available
- Authors
-
Ehab M. Elzayat, Abdelrahman Y. Sherif, Ahmad Abdul-Wahhab Shahba, Mohsin Kazi, Mohammed Alyahya, Hany W. DarwishList of authors in order
- Landing page
-
https://doi.org/10.1515/chem-2024-0070Publisher landing page
- PDF URL
-
https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdfDirect OA link when available
- Concepts
-
Thymoquinone, Chemistry, Chromatography, Active ingredient, Degradation (telecommunications), Bioavailability, Ingredient, In silico, High-performance liquid chromatography, Ibuprofen, Pharmacology, Antioxidant, Computer science, Gene, Telecommunications, Medicine, Food science, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
3Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3Per-year citation counts (last 5 years)
- References (count)
-
46Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401243272 |
|---|---|
| doi | https://doi.org/10.1515/chem-2024-0070 |
| ids.doi | https://doi.org/10.1515/chem-2024-0070 |
| ids.openalex | https://openalex.org/W4401243272 |
| fwci | 4.1711365 |
| type | article |
| title | Development and validation of a stability indicating UPLC-DAD method coupled with MS-TQD for ramipril and thymoquinone in bioactive SNEDDS with in silico toxicity analysis of ramipril degradation products |
| biblio.issue | 1 |
| biblio.volume | 22 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T12750 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991000294685364 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2707 |
| topics[0].subfield.display_name | Complementary and alternative medicine |
| topics[0].display_name | Nigella sativa pharmacological applications |
| topics[1].id | https://openalex.org/T12817 |
| topics[1].field.id | https://openalex.org/fields/30 |
| topics[1].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[1].score | 0.9700000286102295 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3004 |
| topics[1].subfield.display_name | Pharmacology |
| topics[1].display_name | Pharmacological Effects of Natural Compounds |
| topics[2].id | https://openalex.org/T13454 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9656000137329102 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Phenothiazines and Benzothiazines Synthesis and Activities |
| is_xpac | False |
| apc_list.value | 1200 |
| apc_list.currency | EUR |
| apc_list.value_usd | 1294 |
| apc_paid.value | 1200 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 1294 |
| concepts[0].id | https://openalex.org/C2779034068 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8600962162017822 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7799650 |
| concepts[0].display_name | Thymoquinone |
| concepts[1].id | https://openalex.org/C185592680 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6994984149932861 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[1].display_name | Chemistry |
| concepts[2].id | https://openalex.org/C43617362 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6009300351142883 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[2].display_name | Chromatography |
| concepts[3].id | https://openalex.org/C45904493 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5890175104141235 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q912807 |
| concepts[3].display_name | Active ingredient |
| concepts[4].id | https://openalex.org/C2779679103 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5536221861839294 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q5251805 |
| concepts[4].display_name | Degradation (telecommunications) |
| concepts[5].id | https://openalex.org/C181389837 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5271315574645996 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q461809 |
| concepts[5].display_name | Bioavailability |
| concepts[6].id | https://openalex.org/C2780589914 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5052970051765442 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q10675206 |
| concepts[6].display_name | Ingredient |
| concepts[7].id | https://openalex.org/C2775905019 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4988443851470947 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q192572 |
| concepts[7].display_name | In silico |
| concepts[8].id | https://openalex.org/C179998833 |
| concepts[8].level | 2 |
| concepts[8].score | 0.43504953384399414 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q381233 |
| concepts[8].display_name | High-performance liquid chromatography |
| concepts[9].id | https://openalex.org/C2779944601 |
| concepts[9].level | 2 |
| concepts[9].score | 0.41754817962646484 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q186969 |
| concepts[9].display_name | Ibuprofen |
| concepts[10].id | https://openalex.org/C98274493 |
| concepts[10].level | 1 |
| concepts[10].score | 0.19781753420829773 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[10].display_name | Pharmacology |
| concepts[11].id | https://openalex.org/C2778004101 |
| concepts[11].level | 2 |
| concepts[11].score | 0.11744669079780579 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q133948 |
| concepts[11].display_name | Antioxidant |
| concepts[12].id | https://openalex.org/C41008148 |
| concepts[12].level | 0 |
| concepts[12].score | 0.09227585792541504 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[12].display_name | Computer science |
| concepts[13].id | https://openalex.org/C104317684 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[13].display_name | Gene |
| concepts[14].id | https://openalex.org/C76155785 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q418 |
| concepts[14].display_name | Telecommunications |
| concepts[15].id | https://openalex.org/C71924100 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[15].display_name | Medicine |
| concepts[16].id | https://openalex.org/C31903555 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q1637030 |
| concepts[16].display_name | Food science |
| concepts[17].id | https://openalex.org/C55493867 |
| concepts[17].level | 1 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[17].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/thymoquinone |
| keywords[0].score | 0.8600962162017822 |
| keywords[0].display_name | Thymoquinone |
| keywords[1].id | https://openalex.org/keywords/chemistry |
| keywords[1].score | 0.6994984149932861 |
| keywords[1].display_name | Chemistry |
| keywords[2].id | https://openalex.org/keywords/chromatography |
| keywords[2].score | 0.6009300351142883 |
| keywords[2].display_name | Chromatography |
| keywords[3].id | https://openalex.org/keywords/active-ingredient |
| keywords[3].score | 0.5890175104141235 |
| keywords[3].display_name | Active ingredient |
| keywords[4].id | https://openalex.org/keywords/degradation |
| keywords[4].score | 0.5536221861839294 |
| keywords[4].display_name | Degradation (telecommunications) |
| keywords[5].id | https://openalex.org/keywords/bioavailability |
| keywords[5].score | 0.5271315574645996 |
| keywords[5].display_name | Bioavailability |
| keywords[6].id | https://openalex.org/keywords/ingredient |
| keywords[6].score | 0.5052970051765442 |
| keywords[6].display_name | Ingredient |
| keywords[7].id | https://openalex.org/keywords/in-silico |
| keywords[7].score | 0.4988443851470947 |
| keywords[7].display_name | In silico |
| keywords[8].id | https://openalex.org/keywords/high-performance-liquid-chromatography |
| keywords[8].score | 0.43504953384399414 |
| keywords[8].display_name | High-performance liquid chromatography |
| keywords[9].id | https://openalex.org/keywords/ibuprofen |
| keywords[9].score | 0.41754817962646484 |
| keywords[9].display_name | Ibuprofen |
| keywords[10].id | https://openalex.org/keywords/pharmacology |
| keywords[10].score | 0.19781753420829773 |
| keywords[10].display_name | Pharmacology |
| keywords[11].id | https://openalex.org/keywords/antioxidant |
| keywords[11].score | 0.11744669079780579 |
| keywords[11].display_name | Antioxidant |
| keywords[12].id | https://openalex.org/keywords/computer-science |
| keywords[12].score | 0.09227585792541504 |
| keywords[12].display_name | Computer science |
| language | en |
| locations[0].id | doi:10.1515/chem-2024-0070 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210229753 |
| locations[0].source.issn | 2391-5420 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2391-5420 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Chemistry |
| locations[0].source.host_organization | https://openalex.org/P4310320322 |
| locations[0].source.host_organization_name | De Gruyter Open |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320322 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Chemistry |
| locations[0].landing_page_url | https://doi.org/10.1515/chem-2024-0070 |
| locations[1].id | pmh:oai:doaj.org/article:8ff68642cc9149889ddcfb84c3de14da |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Chemistry, Vol 22, Iss 1, Pp 2055-63 (2024) |
| locations[1].landing_page_url | https://doaj.org/article/8ff68642cc9149889ddcfb84c3de14da |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5013178388 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5177-4477 |
| authorships[0].author.display_name | Ehab M. Elzayat |
| authorships[0].countries | SA |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[0].institutions[0].id | https://openalex.org/I28022161 |
| authorships[0].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[0].institutions[0].country_code | SA |
| authorships[0].institutions[0].display_name | King Saud University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ehab M. Elzayat |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[1].author.id | https://openalex.org/A5033659306 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-1842-6010 |
| authorships[1].author.display_name | Abdelrahman Y. Sherif |
| authorships[1].countries | SA |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[1].institutions[0].id | https://openalex.org/I28022161 |
| authorships[1].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[1].institutions[0].country_code | SA |
| authorships[1].institutions[0].display_name | King Saud University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Abdelrahman Y. Sherif |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[2].author.id | https://openalex.org/A5043701828 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4509-8219 |
| authorships[2].author.display_name | Ahmad Abdul-Wahhab Shahba |
| authorships[2].countries | SA |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[2].institutions[0].id | https://openalex.org/I28022161 |
| authorships[2].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[2].institutions[0].country_code | SA |
| authorships[2].institutions[0].display_name | King Saud University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ahmad Abdul-Wahhab Shahba |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[3].author.id | https://openalex.org/A5054971303 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5611-0378 |
| authorships[3].author.display_name | Mohsin Kazi |
| authorships[3].countries | SA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[3].institutions[0].id | https://openalex.org/I28022161 |
| authorships[3].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[3].institutions[0].country_code | SA |
| authorships[3].institutions[0].display_name | King Saud University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mohsin Kazi |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[4].author.id | https://openalex.org/A5057406793 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-9966-3212 |
| authorships[4].author.display_name | Mohammed Alyahya |
| authorships[4].countries | SA |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[4].institutions[0].id | https://openalex.org/I28022161 |
| authorships[4].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[4].institutions[0].country_code | SA |
| authorships[4].institutions[0].display_name | King Saud University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mohammed Alyahya |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Pharmaceutics, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[5].author.id | https://openalex.org/A5069114214 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3437-2748 |
| authorships[5].author.display_name | Hany W. Darwish |
| authorships[5].countries | SA |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| authorships[5].institutions[0].id | https://openalex.org/I28022161 |
| authorships[5].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[5].institutions[0].country_code | SA |
| authorships[5].institutions[0].display_name | King Saud University |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Hany W. Darwish |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University , Riyadh , Saudi Arabia |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Development and validation of a stability indicating UPLC-DAD method coupled with MS-TQD for ramipril and thymoquinone in bioactive SNEDDS with in silico toxicity analysis of ramipril degradation products |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12750 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991000294685364 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2707 |
| primary_topic.subfield.display_name | Complementary and alternative medicine |
| primary_topic.display_name | Nigella sativa pharmacological applications |
| related_works | https://openalex.org/W4243609823, https://openalex.org/W4249953473, https://openalex.org/W4231699368, https://openalex.org/W4244777403, https://openalex.org/W2038129006, https://openalex.org/W2162150293, https://openalex.org/W2349942205, https://openalex.org/W2909057104, https://openalex.org/W4395446508, https://openalex.org/W2381544897 |
| cited_by_count | 3 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1515/chem-2024-0070 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210229753 |
| best_oa_location.source.issn | 2391-5420 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2391-5420 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Chemistry |
| best_oa_location.source.host_organization | https://openalex.org/P4310320322 |
| best_oa_location.source.host_organization_name | De Gruyter Open |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320322 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Chemistry |
| best_oa_location.landing_page_url | https://doi.org/10.1515/chem-2024-0070 |
| primary_location.id | doi:10.1515/chem-2024-0070 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210229753 |
| primary_location.source.issn | 2391-5420 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2391-5420 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Chemistry |
| primary_location.source.host_organization | https://openalex.org/P4310320322 |
| primary_location.source.host_organization_name | De Gruyter Open |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320322 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.degruyter.com/document/doi/10.1515/chem-2024-0070/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Chemistry |
| primary_location.landing_page_url | https://doi.org/10.1515/chem-2024-0070 |
| publication_date | 2024-01-01 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4293029499, https://openalex.org/W4306725817, https://openalex.org/W4307128310, https://openalex.org/W2025592056, https://openalex.org/W2341071777, https://openalex.org/W2126153146, https://openalex.org/W2151000913, https://openalex.org/W3164885089, https://openalex.org/W2314290435, https://openalex.org/W2959529423, https://openalex.org/W2292079023, https://openalex.org/W3182273681, https://openalex.org/W4296118135, https://openalex.org/W1970681140, https://openalex.org/W3047931358, https://openalex.org/W3016252726, https://openalex.org/W2944653489, https://openalex.org/W3005128081, https://openalex.org/W3157794087, https://openalex.org/W2030159680, https://openalex.org/W1981373280, https://openalex.org/W4387460915, https://openalex.org/W3185790423, https://openalex.org/W2895671252, https://openalex.org/W4285393154, https://openalex.org/W2574504416, https://openalex.org/W4388492050, https://openalex.org/W3208784266, https://openalex.org/W2077940538, https://openalex.org/W4377115756, https://openalex.org/W2069043371, https://openalex.org/W2604643869, https://openalex.org/W2055495980, https://openalex.org/W4322743555, https://openalex.org/W2018979823, https://openalex.org/W2060440041, https://openalex.org/W2115388376, https://openalex.org/W2584294284, https://openalex.org/W2140018321, https://openalex.org/W3006756219, https://openalex.org/W2804846127, https://openalex.org/W4295086997, https://openalex.org/W2026537351, https://openalex.org/W3136433542, https://openalex.org/W1538928067, https://openalex.org/W2086366274 |
| referenced_works_count | 46 |
| abstract_inverted_index.( | 214 |
| abstract_inverted_index.) | 217 |
| abstract_inverted_index.2 | 216 |
| abstract_inverted_index.a | 32, 64, 96, 180, 240 |
| abstract_inverted_index.r | 215 |
| abstract_inverted_index.RP | 111, 164, 190, 208, 259, 296 |
| abstract_inverted_index.T3 | 177 |
| abstract_inverted_index.TQ | 192, 298 |
| abstract_inverted_index.To | 88 |
| abstract_inverted_index.an | 26, 175 |
| abstract_inverted_index.at | 179 |
| abstract_inverted_index.be | 287 |
| abstract_inverted_index.in | 9, 146, 159, 263 |
| abstract_inverted_index.of | 3, 6, 45, 54, 86, 92, 110, 183, 232, 244, 253, 258, 295, 302 |
| abstract_inverted_index.on | 21 |
| abstract_inverted_index.to | 17, 80, 105, 118, 122, 136, 289 |
| abstract_inverted_index.210 | 194 |
| abstract_inverted_index.254 | 196 |
| abstract_inverted_index.3.2 | 247 |
| abstract_inverted_index.HSS | 176 |
| abstract_inverted_index.RP. | 87 |
| abstract_inverted_index.TQ, | 166, 210 |
| abstract_inverted_index.TQ. | 113 |
| abstract_inverted_index.The | 1, 114, 126, 186, 199, 224, 249 |
| abstract_inverted_index.and | 72, 112, 141, 165, 191, 195, 209, 221, 229, 235, 251, 278, 293, 297 |
| abstract_inverted_index.can | 286 |
| abstract_inverted_index.due | 16 |
| abstract_inverted_index.for | 189, 206 |
| abstract_inverted_index.has | 12 |
| abstract_inverted_index.its | 41, 73 |
| abstract_inverted_index.may | 59 |
| abstract_inverted_index.nm, | 197 |
| abstract_inverted_index.oil | 70 |
| abstract_inverted_index.run | 242 |
| abstract_inverted_index.the | 46, 51, 83, 90, 93, 108, 283, 291, 300, 303 |
| abstract_inverted_index.two | 254 |
| abstract_inverted_index.was | 29, 78, 103, 116, 156 |
| abstract_inverted_index.(MS) | 135 |
| abstract_inverted_index.0.25 | 184 |
| abstract_inverted_index.UPLC | 201 |
| abstract_inverted_index.both | 207, 233 |
| abstract_inverted_index.drug | 34, 124 |
| abstract_inverted_index.flow | 181 |
| abstract_inverted_index.form | 60 |
| abstract_inverted_index.have | 49 |
| abstract_inverted_index.into | 31 |
| abstract_inverted_index.less | 245 |
| abstract_inverted_index.mass | 133 |
| abstract_inverted_index.min. | 248 |
| abstract_inverted_index.none | 44 |
| abstract_inverted_index.rate | 182 |
| abstract_inverted_index.skin | 276 |
| abstract_inverted_index.than | 246 |
| abstract_inverted_index.that | 58 |
| abstract_inverted_index.time | 243 |
| abstract_inverted_index.used | 79, 288 |
| abstract_inverted_index.were | 130, 145, 172, 193, 260, 280 |
| abstract_inverted_index.with | 168, 211 |
| abstract_inverted_index.(BCO) | 71 |
| abstract_inverted_index.(RP), | 25 |
| abstract_inverted_index.(TQ), | 77 |
| abstract_inverted_index.6.3). | 269 |
| abstract_inverted_index.Derek | 161, 266 |
| abstract_inverted_index.Nexus | 151, 162, 267 |
| abstract_inverted_index.along | 167 |
| abstract_inverted_index.black | 68 |
| abstract_inverted_index.cumin | 69 |
| abstract_inverted_index.drugs | 234 |
| abstract_inverted_index.mass, | 140 |
| abstract_inverted_index.short | 241 |
| abstract_inverted_index.their | 18, 138, 142, 154, 169, 236 |
| abstract_inverted_index.these | 55 |
| abstract_inverted_index.using | 132, 149, 158, 174, 262 |
| abstract_inverted_index.which | 38 |
| abstract_inverted_index.while | 153 |
| abstract_inverted_index.(UPLC) | 101 |
| abstract_inverted_index.0.9995 | 220 |
| abstract_inverted_index.SNEDDS | 66 |
| abstract_inverted_index.Zeneth | 150 |
| abstract_inverted_index.agent, | 28 |
| abstract_inverted_index.assess | 89 |
| abstract_inverted_index.column | 178 |
| abstract_inverted_index.during | 61, 299 |
| abstract_inverted_index.gained | 13 |
| abstract_inverted_index.impact | 20 |
| abstract_inverted_index.liquid | 99 |
| abstract_inverted_index.method | 102, 202, 225, 285 |
| abstract_inverted_index.silico | 147, 160, 264 |
| abstract_inverted_index.stress | 120 |
| abstract_inverted_index.system | 36 |
| abstract_inverted_index.values | 218 |
| abstract_inverted_index.within | 239 |
| abstract_inverted_index.0.9998, | 222 |
| abstract_inverted_index.Several | 270 |
| abstract_inverted_index.damage, | 275 |
| abstract_inverted_index.effects | 53 |
| abstract_inverted_index.enhance | 82 |
| abstract_inverted_index.further | 81 |
| abstract_inverted_index.greatly | 39 |
| abstract_inverted_index.mL/min. | 185 |
| abstract_inverted_index.measure | 107 |
| abstract_inverted_index.patient | 22 |
| abstract_inverted_index.safety. | 23 |
| abstract_inverted_index.studies | 48 |
| abstract_inverted_index.(version | 268 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 43 |
| abstract_inverted_index.Overall, | 282 |
| abstract_inverted_index.Ramipril | 24 |
| abstract_inverted_index.activity | 85 |
| abstract_inverted_index.alkaline | 255 |
| abstract_inverted_index.analysis | 231 |
| abstract_inverted_index.analyzed | 131 |
| abstract_inverted_index.assessed | 157 |
| abstract_inverted_index.chemical | 143 |
| abstract_inverted_index.delivery | 35 |
| abstract_inverted_index.enhanced | 40 |
| abstract_inverted_index.evaluate | 290 |
| abstract_inverted_index.precise, | 228 |
| abstract_inverted_index.previous | 47 |
| abstract_inverted_index.products | 5, 57, 129, 238, 257 |
| abstract_inverted_index.proposed | 94, 304 |
| abstract_inverted_index.provided | 226 |
| abstract_inverted_index.software | 265 |
| abstract_inverted_index.storage. | 62 |
| abstract_inverted_index.toxicity | 155, 250, 271 |
| abstract_inverted_index.(SNEDDS), | 37 |
| abstract_inverted_index.Moreover, | 63 |
| abstract_inverted_index.accurate, | 227 |
| abstract_inverted_index.attention | 15 |
| abstract_inverted_index.bioactive | 65, 74 |
| abstract_inverted_index.detection | 187 |
| abstract_inverted_index.determine | 137 |
| abstract_inverted_index.developed | 104, 200, 284 |
| abstract_inverted_index.exceeding | 219 |
| abstract_inverted_index.exhibited | 203 |
| abstract_inverted_index.including | 273 |
| abstract_inverted_index.integrity | 294 |
| abstract_inverted_index.linearity | 205 |
| abstract_inverted_index.molecular | 139 |
| abstract_inverted_index.molecules | 8 |
| abstract_inverted_index.potential | 19 |
| abstract_inverted_index.predicted | 148, 261 |
| abstract_inverted_index.products, | 171 |
| abstract_inverted_index.resulting | 127 |
| abstract_inverted_index.separated | 173 |
| abstract_inverted_index.software, | 152 |
| abstract_inverted_index.software. | 163 |
| abstract_inverted_index.stability | 91, 292 |
| abstract_inverted_index.subjected | 117 |
| abstract_inverted_index.validated | 97 |
| abstract_inverted_index.acceptable | 204 |
| abstract_inverted_index.conditions | 121 |
| abstract_inverted_index.containing | 67 |
| abstract_inverted_index.endpoints, | 272 |
| abstract_inverted_index.facilitate | 123 |
| abstract_inverted_index.predicted. | 281 |
| abstract_inverted_index.structures | 144 |
| abstract_inverted_index.accelerated | 119 |
| abstract_inverted_index.chromosomal | 274 |
| abstract_inverted_index.coefficient | 213 |
| abstract_inverted_index.correlation | 212 |
| abstract_inverted_index.degradation | 4, 56, 128, 170, 237, 256 |
| abstract_inverted_index.development | 301 |
| abstract_inverted_index.formulation | 115 |
| abstract_inverted_index.ingredient, | 75 |
| abstract_inverted_index.significant | 14 |
| abstract_inverted_index.therapeutic | 7, 84 |
| abstract_inverted_index.wavelengths | 188 |
| abstract_inverted_index.degradation. | 125 |
| abstract_inverted_index.formulation, | 95 |
| abstract_inverted_index.formulation. | 306 |
| abstract_inverted_index.formulations | 11 |
| abstract_inverted_index.incorporated | 30 |
| abstract_inverted_index.investigated | 50 |
| abstract_inverted_index.mutagenicity | 252 |
| abstract_inverted_index.spectroscopy | 134 |
| abstract_inverted_index.thymoquinone | 76 |
| abstract_inverted_index.respectively. | 198, 223 |
| abstract_inverted_index.toxicological | 52 |
| abstract_inverted_index.chromatography | 100 |
| abstract_inverted_index.concentrations | 109 |
| abstract_inverted_index.identification | 2 |
| abstract_inverted_index.pharmaceutical | 10 |
| abstract_inverted_index.sensitization, | 277 |
| abstract_inverted_index.simultaneously | 106 |
| abstract_inverted_index.hepatotoxicity, | 279 |
| abstract_inverted_index.high-resolution | 230 |
| abstract_inverted_index.antihypertensive | 27, 305 |
| abstract_inverted_index.bioavailability. | 42 |
| abstract_inverted_index.self-nanoemulsifying | 33 |
| abstract_inverted_index.ultrahigh-performance | 98 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5033659306 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I28022161 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.89155774 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |